Sánchez-Cazorla Eloísa, Temes-Álvarez Borja, Oliveros-Martínez Pilar, Fortes-González Pedro, García-Murias María, Barcia de la Iglesia Ana, Carrera Noa, García-González Miguel Ángel
Group of Genetics and Developmental Biology of Renal Disease, Laboratory of Nephrology, No. 11, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain; Genomic Medicine Group, Clinical University Hospital of Santiago de Compostela (CHUS), 15706 Santiago de Compostela, Spain; RICORS 2040 (Kidney Disease), ISCIII, Santiago de Compostela, Spain.
RICORS 2040 (Kidney Disease), ISCIII, Santiago de Compostela, Spain; Nephrology service, Clinical University Hospital of Ourense (CHUOU), Ourense, Spain.
Nefrologia (Engl Ed). 2025 May;45(5):369-380. doi: 10.1016/j.nefroe.2025.04.007. Epub 2025 Apr 28.
The UMOD gene encodes the uromodulin protein, which plays a crucial role in renal function. Genetic alterations affecting its correct function are mainly related to Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD), progressive renal failure and hyperuricaemia, among other variable clinical phenotypes. In the Galician population there are recurrent mutations in this gene, this study aims to phenotypically characterize the recurrent variants to improve the prognosis and management strategies of affected patients.
In a Galician population characterized by high genetic conservation, a retrospective cohort study was conducted with 37 patients from 15 families carrying recurrent variants in UMOD (p.C255Y and p.Q316P, from transcript NM_001008389.3). Clinical data were collected, including renal function, hyperuricemia, hypertension and presence of renal cysts. Genomic analyses were performed by NGS and Sanger sequencing, variant classification were conducted according to ACMG guidelines. Statistical comparisons were performed using Mann-Whitney, Chi-square and Fisher tests, with Benjamini-Hochberg correction for multiple testing.
The cohort included 28 carriers of p.C255Y and 9 of p.Q316P genetic variants. Both variants affect highly conserved domains with low tolerance to amino acid changes, which alters protein function and has clinical effects in patients. Hyperuricemia was observed in 76% of p.C255Y carriers and 50% of p.Q316P carriers, while interestingly only the first variant was associated with episodes of gout. Renal cysts and hypertension were identified in about half of the patients, independently of variant type. Kaplan-Meier curves suggested an earlier progression to hyperuricemia and advanced chronic kidney disease (CKD) in p.C255Y carriers, although without reaching statistical significance.
Recurrent UMOD mutations in a Galician cohort revealed shared clinical features, including hyperuricemia and CKD progression, with phenotypic variability influenced by age and additional genetic modifiers. The findings highlight the prognostic value of genotype-phenotype correlations and the need for tailored clinical management in ADTKD patients.
UMOD基因编码尿调节蛋白,该蛋白在肾功能中起关键作用。影响其正常功能的基因改变主要与常染色体显性遗传性肾小管间质性肾病(ADTKD)、进行性肾衰竭和高尿酸血症以及其他多种临床表型有关。在加利西亚人群中,该基因存在复发性突变,本研究旨在对这些复发性变异进行表型特征分析,以改善受影响患者的预后和管理策略。
在一个具有高度遗传保守性的加利西亚人群中,对来自15个家庭的37例携带UMOD基因复发性变异(来自转录本NM_001008389.3的p.C255Y和p.Q316P)的患者进行了一项回顾性队列研究。收集了临床数据,包括肾功能、高尿酸血症、高血压和肾囊肿的存在情况。通过二代测序(NGS)和桑格测序进行基因组分析,根据美国医学遗传学与基因组学学会(ACMG)指南进行变异分类。使用曼-惠特尼检验、卡方检验和费舍尔检验进行统计比较,并采用本杰明尼-霍奇伯格校正法进行多重检验校正。
该队列包括28例p.C255Y变异携带者和9例p.Q316P变异携带者。这两种变异均影响高度保守的结构域,对氨基酸变化的耐受性较低,从而改变蛋白质功能并在患者中产生临床影响。76%的p.C255Y变异携带者和50%的p.Q316P变异携带者出现高尿酸血症,而有趣的是,只有第一种变异与痛风发作有关。约一半的患者发现有肾囊肿和高血压,与变异类型无关。卡普兰-迈耶曲线表明,p.C255Y变异携带者向高尿酸血症和晚期慢性肾脏病(CKD)进展得更早,尽管未达到统计学显著性。
加利西亚队列中的UMOD基因复发性突变揭示了共同的临床特征,包括高尿酸血症和CKD进展,其表型变异性受年龄和其他基因修饰因子影响。这些发现突出了基因型-表型相关性的预后价值以及对ADTKD患者进行个性化临床管理的必要性。